About this trial
RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future.
PURPOSE: This laboratory study is looking at biomarkers in patients with respiratory tract dysplasia or lung cancer, head and neck cancer, or aerodigestive tract cancer.
Eligibility criteria
Qualifiers
Diagnosis of extensive and severe dysplasia of the respiratory epithelium
Those without dysplasia of the respiratory epithelium
Recruited from the SPORE Tissue Procurement Screening Project or by private or academic physicians (for patients with moderate or severe dysplasia)
Survived 1 or more aerodigestive system carcinoma for ≥ 1 year
Disqualifiers
None
Trial design
Treatments tested in this trial
- immunohistochemistry staining method
- laboratory biomarker analysis
- sputum cytology
- biopsy
Treatment groups
Sponsors and collaborators
University of Colorado, Denver
Lead sponsor
National Cancer Institute (NCI)
Collaborator